Tonix Pharmaceuticals: FDA AdCom News Positive, But Making Bull Case Is Problematic
Tonix Pharma (TNXP) has submitted an NDA for its candidate TNX-102 SL for fibromyalgia, with a PDUFA date set for August 15, 2025. See why I'm on the sidelines.
AHA/ASA Journals19h
XBP1s-EDEM2 Prevents the Onset and Development of HFpEF by Ameliorating Cardiac Lipotoxicity
BACKGROUND: Morbidity and mortality of heart failure with preserved ejection fraction (HFpEF) is increased in metabolic disorders. However, options for preventing and treating these prevalent outcomes ...